JP2019515915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515915A5 JP2019515915A5 JP2018555273A JP2018555273A JP2019515915A5 JP 2019515915 A5 JP2019515915 A5 JP 2019515915A5 JP 2018555273 A JP2018555273 A JP 2018555273A JP 2018555273 A JP2018555273 A JP 2018555273A JP 2019515915 A5 JP2019515915 A5 JP 2019515915A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- aryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326431P | 2016-04-22 | 2016-04-22 | |
| US62/326,431 | 2016-04-22 | ||
| PCT/US2017/029102 WO2017185083A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515915A JP2019515915A (ja) | 2019-06-13 |
| JP2019515915A5 true JP2019515915A5 (https=) | 2020-06-11 |
Family
ID=60117062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555273A Pending JP2019515915A (ja) | 2016-04-22 | 2017-04-24 | 甲状腺ベータアゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190134069A1 (https=) |
| EP (1) | EP3445372B1 (https=) |
| JP (1) | JP2019515915A (https=) |
| KR (1) | KR102407053B1 (https=) |
| CN (3) | CN110200978B (https=) |
| AU (2) | AU2017252122B2 (https=) |
| BR (1) | BR112018071559B1 (https=) |
| CA (1) | CA3021677C (https=) |
| MX (1) | MX2018012904A (https=) |
| WO (1) | WO2017185083A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| JP2025520449A (ja) * | 2022-06-15 | 2025-07-03 | バイキング セラピューティクス，インコーポレーテッド | Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| US5091552A (en) | 1986-06-30 | 1992-02-25 | Board Of Regents, The University Of Texas System | Novel antitumor aldophosphamide analogs |
| ATE131825T1 (de) | 1990-06-13 | 1996-01-15 | Arnold Glazier | Phosphorylierte prodrugs |
| US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| ATE199906T1 (de) | 1993-06-29 | 2001-04-15 | Mitsubishi Chem Corp | Phosphonat-nukleotid ester-derivate |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| DK0999825T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| CA2534484A1 (en) | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| CA2543132A1 (en) * | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| WO2006128058A2 (en) | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CA2638753A1 (en) * | 2004-12-08 | 2006-06-15 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
| EP1987827A1 (en) * | 2006-02-20 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Novel pharmaceutical |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| HUE038366T2 (hu) * | 2010-08-16 | 2018-10-29 | Allergan Inc | Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| EP3259246B1 (en) * | 2015-02-20 | 2023-03-22 | Oregon Health & Science University | Derivatives of sobetirome |
| EP3423379B1 (en) * | 2016-02-29 | 2020-04-01 | Philip Morris Products S.a.s. | Hinge-lid container and blank |
| CN109475121B (zh) * | 2016-05-18 | 2021-06-25 | 俄勒冈健康科学大学 | 苏比替罗衍生物 |
-
2017
- 2017-04-24 CA CA3021677A patent/CA3021677C/en active Active
- 2017-04-24 EP EP17786795.9A patent/EP3445372B1/en active Active
- 2017-04-24 MX MX2018012904A patent/MX2018012904A/es unknown
- 2017-04-24 KR KR1020187033321A patent/KR102407053B1/ko active Active
- 2017-04-24 BR BR112018071559-0A patent/BR112018071559B1/pt active IP Right Grant
- 2017-04-24 CN CN201910397947.3A patent/CN110200978B/zh active Active
- 2017-04-24 JP JP2018555273A patent/JP2019515915A/ja active Pending
- 2017-04-24 AU AU2017252122A patent/AU2017252122B2/en active Active
- 2017-04-24 CN CN201780038675.7A patent/CN109641003A/zh active Pending
- 2017-04-24 CN CN202110804956.7A patent/CN113730421A/zh active Pending
- 2017-04-24 US US16/095,224 patent/US20190134069A1/en not_active Abandoned
- 2017-04-24 WO PCT/US2017/029102 patent/WO2017185083A1/en not_active Ceased
-
2023
- 2023-04-14 AU AU2023202321A patent/AU2023202321B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007512359A5 (https=) | ||
| JP2019531346A5 (https=) | ||
| JP2019515915A5 (https=) | ||
| JP2011522789A5 (https=) | ||
| JP2014514290A5 (https=) | ||
| JP2010506854A5 (https=) | ||
| JP2009530306A5 (https=) | ||
| JP2020536863A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| JP2015062072A5 (https=) | ||
| JP2014508781A5 (https=) | ||
| JPWO2020123827A5 (https=) | ||
| JP2018516888A5 (https=) | ||
| JP2016537358A5 (https=) | ||
| JP2016505586A5 (https=) | ||
| JP2009532453A5 (https=) | ||
| RU2009117642A (ru) | Применение спирооксиндоловых соединений в качестве терапевтических средств | |
| JP2016500107A5 (ja) | グルタミナーゼ阻害剤およびその使用方法 | |
| JP2018505196A5 (https=) | ||
| JP2019529518A5 (https=) | ||
| JP2016531871A5 (https=) | ||
| JP2011527345A5 (https=) | ||
| JP2018530582A5 (https=) | ||
| JP2014505017A5 (https=) | ||
| JP2014527969A5 (https=) |